STOCK TITAN

SQZ Biotechnologies to Present at the 4th Annual Evercore ISI HealthCONx Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

SQZ Biotechnologies (NYSE: SQZ) announced its participation in the 4th Annual Evercore ISI HealthCONx Conference on December 1. CEO Armon Sharei, Ph.D., will provide a corporate overview during a fireside chat scheduled from 9:15-9:35 am ET. SQZ will also conduct one-on-one meetings with attendees. Details regarding the presentation and a webcast will be accessible on the company's website for 90 days post-event. SQZ focuses on advancing cell therapies across oncology, autoimmune, and infectious disease sectors.

Positive
  • None.
Negative
  • None.

WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the 4th Annual Evercore ISI HealthCONx Conference on December 1st. Armon Sharei, Ph.D., Chief Executive Officer, will present a corporate overview and the company will be hosting one-on-one meetings.

PRESENTATION DETAILS

Wednesday, December 1
4th Annual Evercore ISI HealthCONx Conference
Fireside Chat
9:15-9:35 am ET
Webcast

Specific conference webcast details and the company’s corporate overview presentation will be available on the Investors & Media section of the SQZ website. The webcast will be available for 90 days following the presentation.

About SQZ Biotechnologies

SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world and has active programs in Oncology, Autoimmune and Infectious Diseases, as well as additional exploratory initiatives to support future pipeline growth. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many cell types to engineer what we believe can be a broad range of potential therapeutics. With demonstrated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could significantly broaden the therapeutic range and accessibility of cell therapies. The company’s first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and infectious diseases, and in immune tolerance for the treatment of autoimmune diseases. For more information, please visit www.sqzbiotech.com.

SQZ Biotechnologies Investor Relations:

investors@sqzbiotech.com

SQZ Biotechnologies Media:

John Lacey

Corporate Communications

john.lacey@sqzbiotech.com

781-392-5514

Source: SQZ Biotechnologies

FAQ

When will SQZ Biotechnologies present at the Evercore ISI HealthCONx Conference?

SQZ Biotechnologies will present on December 1 during the 4th Annual Evercore ISI HealthCONx Conference.

Who is presenting for SQZ Biotechnologies at the conference?

Armon Sharei, Ph.D., the CEO of SQZ Biotechnologies, will present at the conference.

What time is the SQZ Biotechnologies presentation scheduled?

The SQZ Biotechnologies fireside chat is scheduled for 9:15-9:35 am ET on December 1.

How can I access the SQZ Biotechnologies conference presentation?

The presentation details and a webcast will be available on the SQZ Biotechnologies website for 90 days after the event.

What areas does SQZ Biotechnologies focus on?

SQZ Biotechnologies focuses on oncology, autoimmune, and infectious diseases, utilizing its proprietary Cell Squeeze® technology.

SQZ

NYSE:SQZ

SQZ Rankings

SQZ Latest News

SQZ Stock Data

12.83M
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link